

AF
GP 1631

DOCKET NO.: ISIS-1158

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1631



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Nielsen et al.

Serial No.: 08/319,411

Corres. and Mail
BOX AF

Group Art Unit: 1631

Filing Date: October 6, 1994

Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACID CONJUGATES

DATE OF DEPOSIT: June 19, 2000

I HEREBY CERTIFY THAT THIS PAPER IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID
ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, DC 20231.

Michael P. Straher
TYPED NAME: Michael P. Straher
REGISTRATION NO.: 38,325

Box NON-FEE

AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- A Preliminary Amendment.
- An Amendment Responsive to the Office Action Dated April 18, 2000.
- An Amendment Supplemental to the Paper filed _____.
- Other: _____.
- Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.

RECEIVED
JUN 22 2000
TC 1600 MAIL ROOM

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1631**

- A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.
- This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- Substitute Pages _____ of the Specification are enclosed.
- An Abstract is enclosed.
- _____ Sheets of Proposed Corrected Drawings are enclosed.
- A Certified Copy of each of the following applications: _____ is enclosed.
- An Associate Power of Attorney is enclosed.
- Information Disclosure Statement.
 - Attached Form 1449.
 - A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- Appended Material as follows: _____.
- Other Material as follows: _____.

JUN 22 2000
TC 1600 MAIL ROOM

RECEIVED

FEE CALCULATION

No Additional Fee is Due.

			SMALL ENTITY		NOT SMALL ENTITY		
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	Fee	RATE	Fee
TOTAL CLAIMS	29	36 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$0
INDEP. CLAIMS	14	15 (3 MINIMUM)	0	\$39 EACH	\$	\$78 EACH	\$0
FIRST PRESENTATION OF MULTIPLE DEPENDENT			\$130		\$	\$260	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME			\$55		\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME			\$190		\$	\$380	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME			\$435		\$	\$870	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME			\$680		\$	\$1360	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME			\$925		\$	\$1850	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID			minus	(\$)	minus	(\$)	
<input type="checkbox"/> TERMINAL DISCLAIMER			\$55		\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE							\$0

A Check is Enclosed in the Foregoing Amount Due.
 Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).

The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is

**RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1631**

further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

The Foregoing Amount Due for Filing this Paper.

Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: June 19, 2000


Michael P. Straher
Registration No. 38,325

Woodcock Washburn Kurtz
Mackiewicz & Norris LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439



SOCKET NO.: ISIS-1158

RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1631

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nielsen, et al.

Serial No.: 08/319,411

Group Art Unit: 1631


Filed: October 6, 1994

Examiner: A. Marschel

For: PEPTIDE NUCLEIC ACID CONJUGATES

I, Michael P. Straher, Registration No. 38,325 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On June 19, 2000



Michael P. Straher
Registration No. 38,325

Box AF
Assistant Commissioner
for Patents
Washington, D.C. 20231

AMENDMENT AND REQUEST FOR RECONSIDERATION

OK TO ENTER
AM, 7-7-00

In response to the Office Action mailed April 18, 2000, in connection with the above-captioned patent application, Applicants respectfully request that the following amendment be entered:

In the claims:

In claim 30, in the eighth line from the end, delete "R3" and substitute --R³-- therefor.